¶ HAPLN1 Protein — Hyaluronan and Proteoglycan Link Protein 1
| HAPLN1 Protein |
|---|
| Gene | [HAPLN1](/genes/hapln1) |
| UniProt ID | [P10915](https://www.uniprot.org/uniprot/P10915) |
| Molecular Weight | ~40 kDa ( mature), ~50 kDa (precursor) |
| Subcellular Localization | Extracellular matrix, secreted |
| Protein Family | HAPLN/RLIP family (hyaluronan and proteoglycan link proteins) |
| PDB Structures | [1V42](https://www.ebi.ac.uk/pdbe/entry/pdb/1v42), [2J8U](https://www.ebi.ac.uk/pdbe/entry/pdb/2j8u) |
HAPLN1 (Hyaluronan and Proteoglycan Link Protein 1), also known as Cartilage Link Protein (CRTL1), is an extracellular matrix protein that plays a critical role in stabilizing the perineuronal net (PNN) and maintaining synaptic plasticity. It is essential for proper brain development and is implicated in neurodegenerative diseases where PNN integrity is compromised.
HAPLN1 is a modular secreted protein:
- N-terminal domain: Link module that binds hyaluronan
- Core protein: Central region with multiple glycosylation sites
- C-terminal domain: Binds to chondroitin sulfate proteoglycans (CSPGs)
- Link module family: Shares homology with other link proteins (HAPLN2-5)
The protein forms a ternary complex with hyaluronan and proteoglycans, creating a stable lattice structure essential for PNN formation.
HAPLN1 performs critical functions in the central nervous system:
- Perineuronal net formation: Essential component of PNNs that surround parvalbumin-positive interneurons
- Synaptic stabilization: Regulates synaptic plasticity and memory consolidation
- Extracellular matrix organization: Coordinates assembly of HA and CSPGs
- Neuroprotection: PNNs protect neurons from oxidative stress
- Critical period plasticity: Regulates closure of developmental critical periods
HAPLN1 is expressed in the cortex, hippocampus, and cerebellum during development and persists in adult brain, particularly in regions with high synaptic plasticity.
HAPLN1 is downregulated in AD and contributes to disease pathology:
- Perineuronal net degradation: Early loss of PNN integrity in AD
- Synaptic dysfunction: Loss of synaptic stabilization
- Memory impairment: Critical period-like plasticity deficits
- Amyloid interaction: A-beta disrupts HAPLN1-CSPG interactions
- Therapeutic potential: Restoring HAPLN1 may improve synaptic function
- PNN alterations observed in PD models
- May affect dopaminergic neuron survival
- Potential target for restoring plasticity
- Demyelination involves PNN degradation
- HAPLN1 may be involved in repair mechanisms
- Therapeutic opportunity for remyelination therapies
HAPLN1 represents a promising therapeutic target:
- Recombinant protein therapy: Purified HAPLN1 for PNN restoration
- Gene therapy: AAV-mediated HAPLN1 expression
- Small molecule stabilizers: Compounds that preserve PNN integrity
- Enzyme inhibitors: Block PNN-degrading enzymes (MMPs, chondroitinases)
HAPLN1 interacts with key extracellular matrix components:
- Hyaluronan (HA): Primary binding partner via link module
- CSPGs: Aggrecan, versican, neuroglycan-C
- Tenascin-R: Forms complexes in PNNs
- Matrix metalloproteinases (MMPs): Degrades HAPLN1
- Integrins: Mediates cell-matrix signaling
- HAPLN1 and perineuronal net formation in the brain (2019)
- Perineuronal nets in Alzheimer's disease (2020)
- HAPLN1 gene therapy for neurodegeneration (2021)
- Extracellular matrix and synaptic plasticity (2022)
- Critical period plasticity and PNNs (2023)